ARLINGTON, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of ...
KALA BIO announced the resignation of Chief Executive Officer, CEO, Mark Iwicki, and the appointment of Todd Bazemore, KALA‘s President and Chief Operating Officer, as interim CEO, effective ...
ARLINGTON, Mass., Feb. 12, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of ...
KALA BIO, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of therapeutics using proprietary nanoparticle-based mucus penetrating particles with an initial ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback